Access to Medicines and the Rhetoric of Responsibility

Ethics and International Affairs 16 (2):57-70 (2002)
  Copy   BIBTEX

Abstract

There is no cure or vaccine for HIV/AIDS. The only life-prolonging treatment available is antiretroviral (ARV) therapy. WHO estimates, however, that less than 5 percent of those who require treatment in developing countries currently enjoy access to these medicines. In Africa fewer than 50,000 people–less than 2 percent of the people in need–currently receive ARV therapy. These facts have elicited strongly divergent reactions, and views about the appropriate response to this crisis have varied widely.The intensity of the debate concerning access to life-prolonging medicines for the treatment of HIV/AIDS, and the heated rhetoric with which they are often conducted, suggest that these disagreements may be rooted in deeper disagreements of value. It is not obvious, however, what disagreements of value are at stake in this debate. By analyzing the statements of scholars, public officials, activist organizations, and private sector representatives, each of whom may endorse very different policy recommendations on access to HIV/AIDS drugs, we have identified and created a typology of the different sources of disagreement in the debate. We conclude that the central disagreements concerning access to medicines arise from competing understandings of how responsibilities for bringing remedy to hardships should be allocated to different agents and institutions. A central lesson that emerges from our analysis is that thinking about “health equity” must extend beyond the explanation and justification of goals, values, and ideals, and engage more honestly with the difficult question of how responsibilities for bringing remedy to health crises should be allocated in complex social contexts.

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 90,593

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Supply of medicines: paternalism, autonomy and reality.D. Prayle & M. Brazier - 1998 - Journal of Medical Ethics 24 (2):93-98.
GlaxoSmithKline and Access to Essential Medicines (B).N. Craig Smith & Anne Duncan - 2005 - Journal of Business Ethics Education 2 (1):123-132.
Bodies of rights and therapeutic markets.João Biehl & Adriana Petryna - 2011 - Social Research: An International Quarterly 78 (2):359-386.
Introduction: Access to Life-Saving Medicines and Intellectual Property Rights.Doris Schroeder - 2011 - Cambridge Quarterly of Healthcare Ethics 20 (2):277-278.
Patent Funded Access to Medicines.Tom Andreassen - 2014 - Developing World Bioethics 15 (3):152-161.
Corporate Responsibilities for Access to Medicines.Klaus M. Leisinger - 2009 - Journal of Business Ethics 85 (S1):3 - 23.

Analytics

Added to PP
2009-01-28

Downloads
54 (#264,075)

6 months
4 (#319,344)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

Human rights and global health: A research program.Thomas W. Pogge - 2005 - Metaphilosophy 36 (1‐2):182-209.
Global health justice.Jennifer Prah Ruger - 2009 - Public Health Ethics 2 (3):261-275.
Applying the contribution principle.Christian Barry - 2005 - Metaphilosophy 36 (1-2):210-227.

View all 8 citations / Add more citations

References found in this work

World Poverty and Human Rights.Thomas Pogge - 2002 - Ethics and International Affairs 19 (1):1-7.
Political Theory and International Relations.Charles R. Beitz - 1979 - Princeton: Princeton University Press.
An essay on rights.Hillel Steiner - 1994 - Oxford, UK ;: Blackwell.
Moral demands in nonideal theory.Liam B. Murphy - 2000 - New York: Oxford University Press.
Distributing responsibilities.David Miller - 2001 - Journal of Political Philosophy 9 (4):453–471.

View all 10 references / Add more references